Changeflow GovPing Pharma & Drug Safety Method of Determining or Influencing Chondrogen...
Routine Rule Added Final

Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued Patent US12600952B2 to AO TECHNOLOGY AG covering methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by increasing TGFβR1, decreasing TGFβR2, or decreasing ACVRL1 expression. The patent has 23 claims and is classified under C07K peptide and C12N biotechnology CPC codes.\n\nCompetitors in cell therapy, regenerative medicine, and cartilage repair research should review this patent to assess potential freedom-to-operate concerns or licensing opportunities. The assignee's technology may affect companies developing MSC-based therapies for orthopedic applications.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Method of determining or influencing the chondrogenic potential of mesenchymal stromal cells

Grant US12600952B2 Kind: B2 Apr 14, 2026

Assignee

AO TECHNOLOGY AG

Inventors

Martin Stoddart, Mauro Alini

Abstract

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and/or decreasing the amount of TGFβR2, and/or decreasing the amount of and/or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

CPC Classifications

C12N 5/0655 C12N 2501/15 C12N 2506/1353 C12N 2510/00 C07K 14/705

Filing Date

2020-07-03

Application No.

17597269

Claims

23

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600952B2

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Biotechnology research Cell therapy
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!